HUTCHMED (China) (HMDCF) Operating Income (2018 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Operating Income came in at $227.3 million in Q1 2021, up 60.7% year-over-year from $141.5 million in Q1 2020, and up 319.28% quarter-over-quarter from $54.2 million in Q2 2020.
Analysis
HUTCHMED (China) (HMDCF) Operating Income (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Operating Income for 4 consecutive years, with $227.3 million the latest figure, recorded in Q1 2021.
- On a quarterly basis, Operating Income rose 60.7% year-over-year to $227.3 million in Q1 2021; TTM through Mar 2021 was $384.5 million, a 1038.27% increase from a year earlier, with the FY2025 full-year figure at -$39.2 million, up 10.4% from the prior year.
- Operating Income was $227.3 million for Q1 2021 at HUTCHMED (China), up from $54.2 million in the prior quarter.
- Over five years, Operating Income peaked at $227.3 million in Q1 2021 and troughed at -$161.1 million in Q4 2018.
- A 4-year average of $16.7 million and a median of $14.8 million in 2018 frame the typical range for Operating Income.
- Across the five-year window, Operating Income slumped 343.04% in 2019 and surged 292.37% in 2020, its largest moves.
- Over 4 years, Operating Income stood at -$161.1 million in 2018, then surged by 76.14% to -$38.4 million in 2019, then jumped by 241.06% to $54.2 million in 2020, then jumped by 319.28% to $227.3 million in 2021.
- The last three Operating Income figures came in at $227.3 million (Q1 2021), $54.2 million (Q2 2020), and $141.5 million (Q1 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn | -365.99 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | 227.32 Mn |
| Jun 30, 2020 | 54.22 Mn |
| Mar 31, 2020 | 141.45 Mn |
| Dec 31, 2019 | -38.43 Mn |
| Sep 30, 2019 | -35.94 Mn |
| Jun 30, 2019 | -108.06 Mn |
| Mar 31, 2019 | 36.05 Mn |
| Dec 31, 2018 | -161.11 Mn |
| Sep 30, 2018 | 14.79 Mn |
| Jun 30, 2018 | 78.70 Mn |
| Mar 31, 2018 | -25.02 Mn |